The company has a portfolio of promising anticancer drugs at various stages of development, from discovery to clinical-proof-of-concept, and seeks suitable partners for late-stage registration trials and eventual commercialization. Aptose Biosciences has two clinical-stage programs and a discovery-stage program that is partnered with another company. Its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, Luxeptinib, is enrolling patients in a Phase 1 study to assess its safety, tolerability, PK, and preliminary efficacy in patients with chronic lymphocytic leukemia or non-Hodgkin lymphomas. The company's oral potent myeloid kinome inhibitor, HM43239, targets a constellation of kinases operative in myeloid malignancies.